Skip to main content

Guido Ferrari, MD

Professor in Surgery
Research Professor in Molecular Genetics and Microbiology
Office: 915 S. Lasalle Street, Sorf Building Room 208, Durham, NC 27710
Campus Mail: DUMC Box 2926 Med Ctr, Durham, NC 27710

The activities of the Ferrari Laboratory are based on both independent basic research and immune monitoring studies. The research revolves around three main areas of interest: class I-mediated cytotoxic CD8+ T cell responses, antibody-dependent cellular cytotoxicity (ADCC), gene expression in NK and T cellular subsets upon infection with HIV-1. With continuous funding over the last 11 years from the NIH and Bill & Melinda Gates Foundation along with many other productive collaborations within and outside of Duke, the Ferrari Lab has expanded its focus of research to include the ontogeny of HIV-1 specific immune responses that work by eliminating HIV-1 infected cells and how these can be induced by AIDS vaccine candidates.

Education and Training

  • M.D., University of Genoa (Italy), 1985

Selected Grants

Publications

Ferrari, G., A. Garcia-Louzao, J. Cox, A. Sambor, P. D’Souza, C. Gray, M. Jaimes, et al. “Establishing PBMC Repository for T Cell Assays Optimization and Proficiency Testing in CTC-VIMC Laboratories.” In Aids Research and Human Retroviruses, 24:127–28. MARY ANN LIEBERT INC, 2008.

Scholars@Duke

Ferrari, G., M. Liu, C. Marking, N. Goonetilleke, M. Betts, C. Gray, B. Haynes, A. McMichael, and K. Weinhold. “Lack of Highly Poly-Functional Epitope-Specific CD8+Memory T Cell Responses during Spontaneous Control of Viremia.” In Aids Research and Human Retroviruses, 24:20–20. MARY ANN LIEBERT INC, 2008.

Scholars@Duke

Liu, M. K., G. Ferrari, J. Salazar, B. Keele, R. L. Tanner, E. Turnbull, M. Mlotshwa, et al. “T Cell Escape in Subjects with Acute HIV-1 Infection.” In Aids Research and Human Retroviruses, 24:6–7. MARY ANN LIEBERT INC, 2008.

Scholars@Duke

Gasper-Smith, Nancy, Deanna M. Crossman, John F. Whitesides, Nadia Mensali, Janet S. Ottinger, Steven G. Plonk, M Anthony Moody, et al. “Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design.” J Virol 82, no. 15 (August 2008): 7700–7710. https://doi.org/10.1128/JVI.00605-08.

Full Text

DREAM Trial Investigators, S., G. R. Dagenais, H. C. Gerstein, R. Holman, A. Budaj, A. Escalante, T. Hedner, et al. “Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.” Diabetes Care 31, no. 5 (May 2008): 1007–14. https://doi.org/10.2337/dc07-1868.

Full Text

D’Souza, P., J. H. Cox, G. Ferrari, N. T. Kunwar, V. Polonis, and M. Sarzotti-Kelsoe. “Endpoint Assays in HIV-1 Vaccine Trials: Functioning in a Good Laboratory Practices Environment.” In Validation of Cell-Based Assays in the GLP Setting: A Practical Guide, 239–75, 2008. https://doi.org/10.1002/9780470987810.ch14.

Full Text

Gorse, Geoffrey J., Lindsey R. Baden, Margaret Wecker, Mark J. Newman, Guido Ferrari, Kent J. Weinhold, Brian D. Livingston, et al. “Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.” Vaccine 26, no. 2 (January 10, 2008): 215–23. https://doi.org/10.1016/j.vaccine.2007.10.061.

Full Text

Russell, Nina D., Barney S. Graham, Michael C. Keefer, M Juliana McElrath, Steve G. Self, Kent J. Weinhold, David C. Montefiori, et al. “Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.” J Acquir Immune Defic Syndr 44, no. 2 (February 1, 2007): 203–12. https://doi.org/10.1097/01.qai.0000248356.48501.ff.

Full Text

Goepfert, Paul A., Georgia D. Tomaras, Helen Horton, David Montefiori, Guido Ferrari, Mark Deers, Gerald Voss, et al. “Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.” Vaccine 25, no. 3 (January 5, 2007): 510–18. https://doi.org/10.1016/j.vaccine.2006.07.050.

Full Text

Pages